Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Saved in:
| Title: | Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused? |
|---|---|
| Authors: | Kemp, Robert1, Prasad, Vinay2,3,4 prasad@ohsu.edu |
| Source: | BMC Medicine. 07/21/2017, Vol. 15, p1-7. 7p. 2 Charts. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
